Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | GSPT1 | P15170 | 10/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 9/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61575 | 1.00 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL21335035 | 0.95 | CRBN (0.91) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL21335027 | 0.95 | CRBN (0.91) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240145 | 0.93 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1403564 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413700 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413473 | 0.92 | CRBN (0.85) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL68157 | 0.92 | CRBN (0.85) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL19808761 | 0.92 | CRBN (0.84) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| Hydrochloric Acid SCHEMBL62087 | 0.91 | CRBN (0.84) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720059-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4629981-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | The Regents Of The University Of Michigan (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4627059-A1 | RECEPTOR- AND DRUG-DEPENDENT REGULATED ON-SITE PRODUCTION OF BIOLOGICALS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2025-10-08 | — | — | EP | claimed |
| EP-4615959-A1 | NOVEL DRUG-INDUCIBLE DEGRADATION TAGS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2025-09-17 | — | — | EP | claimed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025096855-A1 | DEGRADERS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | claimed |
| EP-4533102-A2 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | The Broad Institute, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| EP-4077680-A1 | DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS | Orionis Biosciences, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115210381-A | Detection of novel degradation-related interactions | 奥里尼斯生物科学股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-115066441-A | Detection of molecular interactions | 奥里尼斯生物科学股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| EP-4048301-A1 | CHIMERIC POLYPEPTIDE FOR REGULATING IMMUNE CELLS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-08-31 | — | — | EP | claimed |
| WO-2022159687-A1 | PHENOTYPIC ASSAY TO IDENTIFY PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| CN-114651061-A | Chimeric polypeptides for modulating immune cells | 施特丁·奈德兰卡克研究所-安东尼·范·列文虎克医院 | 2022-06-21 | — | — | CN | claimed |
| WO-2022093919-A1 | INHIBITORS OF EXO1 IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022093789-A1 | SMALL MOLECULE INHIBITORS OF APEX, ALONE AND IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT GROWTH OF CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220098251-A1 | PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-31 | — | — | US | claimed |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | NORTHWESTERN UNIVERSITY | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098251-A1 | PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS | RPS27A, STUB1, MST1R | CRBN 680/4885GSPT1 51/4885DDB1 426/4885 |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | IDO1, IDO2, KMO | CRBN 176/4885GSPT1 3024/4885DDB1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.